Cue Biopharma, Inc. shareholders approved Adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation of proxies in the event that there are insufficient votes for, or otherwise in connection with, Proposal 1 and/or Proposal 2.
“The Company’s stockholders approved the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation of proxies in the event that there are insufficient votes for, or otherwise in connection with, Proposal 1 and/or Proposal 2 (“Proposal 3”), with votes cast as follows: For Against Abstain Broker Non-Votes 1,302,751 582,084 11,622 -”
Shareholder Votes
Cue Biopharma, Inc. shareholders approved 2026 Plan.
“The Company’s stockholders approved the 2026 Plan (“Proposal 2”), with votes cast as follows: For Against Abstain Broker Non-Votes 1,261,296 632,474 2,687 -”
Shareholder Votes
Cue Biopharma, Inc. shareholders approved Issuance of shares of common stock upon the exercise of certain warrants issued by the Company in May 2026 in connection with a licensing transaction and related private placement.
“The Company’s stockholders approved, in accordance with Nasdaq Listing Rule 5635(a), (c) and (d), the issuance of shares of common stock upon the exercise of certain warrants issued by the Company in May 2026 in connection with a licensing transaction and related private placement (“Proposal 1”), with votes cast as follows: For Against Abstain Broker Non-Votes 1,782,133 113,311 1,013 -”
Colin Sandercock changed role as Senior Vice President, Intellectual Property at Cue Biopharma, Inc..
“Mr. Sandercock will continue to serve as the Company’s Senior Vice President, Intellectual Property.”
Viola Meehan was appointed as director at Cue Biopharma, Inc..
“On May 30, 2026, the Board appointed each of Daniel Camardo and Viola Meehan as directors of the Company, to hold office for a one-year term and until his or her resignation or removal or his or her successors are duly elected and qualified.”
Daniel Camardo was appointed as director at Cue Biopharma, Inc..
“On May 30, 2026, the Board appointed each of Daniel Camardo and Viola Meehan as directors of the Company, to hold office for a one-year term and until his or her resignation or removal or his or her successors are duly elected and qualified.”
Michael Meluzio was appointed as Vice President, Principal Accounting Officer at Cue Biopharma, Inc..
“On June 1, 2026, the Board appointed Michael Meluzio as the Company’s Vice President, Principal Accounting Officer, to serve as the Company’s principal accounting officer, effective June 1, 2026.”
Sumita Ray was appointed as Chief Legal & Compliance Officer and Corporate Secretary at Cue Biopharma, Inc..
“On June 1, 2026, the Board appointed Sumita Ray, JD, as the Company’s Chief Legal & Compliance Officer and Corporate Secretary, effective June 1, 2026.”
Patrick Verheyen departed as member of the Board of Directors at Cue Biopharma, Inc..
“On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.”
Frank Morich departed as member of the Board of Directors at Cue Biopharma, Inc..
“On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.”
Peter Kiener departed as member of the Board of Directors at Cue Biopharma, Inc..
“On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.”
Jill Broadfoot departed as member of the Board of Directors at Cue Biopharma, Inc..
“On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.”
Earnings Releases
Cue Biopharma, Inc. reported the quarter ended March 31, 2026 results: revenue $5.7 million, net income Net loss ... $5.2 million, EPS $(1.08) per common share – basic and diluted.
“to the FDA in the second half of 2026 • Phase 1 first-in-human study expected to be initiated by year-end 2026. First Quarter 2026 Financial Results First quarter revenue was $5.7 million compared to $0.4 million in the first quarter of 2025. The revenue earned during the three months ended March 31, 2026 was related to the Boehringer Ingelheim collaboration and”
Equity Issuances
Cue Biopharma, Inc. issued up to 551,724 shares of common stock of warrant to Ascendant Health Sciences Ltd..
“the Company agreed to issue to the Licensor at an initial closing (the “Initial Closing”) pre-funded warrants (the “Initial Closing Pre-Funded Warrants”) to purchase up to 551,724 shares of common stock, $0.001 par value per share, of the Company (the “Common Stock”), as partial consideration for the license and rights granted under the License Agreement.”
Material Agreements
Cue Biopharma, Inc. entered into License Agreement with Ascendant Health Sciences Ltd. valued at $15.0 million as the upfront payment, up to an aggregate of $676.5 million in additional potential m (effective 2026-04-30).
“On April 30, 2026, Cue Biopharma, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Ascendant Health Sciences Ltd., a Cayman Limited Company (the “Licensor”).”
Lucinda Warren resigned as Interim President and Chief Executive Officer at Cue Biopharma, Inc..
“Dr. Lin will succeed Lucinda Warren whose resignation as Interim President and Chief Executive Officer was effective as of April 30, 2026”
Shao-Lee Lin was appointed as Member of the Board at Cue Biopharma, Inc..
“On April 27, 2026, the Board appointed Dr. Shao-Lee Lin as the Company’s President and Chief Executive Officer and as a member of the Board, effective as of her commencement of employment with the Company, which began on April 30, 2026”
Shao-Lee Lin was appointed as President and Chief Executive Officer at Cue Biopharma, Inc..
“On April 27, 2026, the Board appointed Dr. Shao-Lee Lin as the Company’s President and Chief Executive Officer and as a member of the Board, effective as of her commencement of employment with the Company, which began on April 30, 2026”
Governance Changes
Cue Biopharma, Inc.: 1-for-30 reverse stock split effected by filing a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (effective 2026-04-23).
“On April 22, 2026, Cue Biopharma, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on April 23, 2026 (the “Effective Time”), a 1-for-30 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”).”
Earnings Releases
Cue Biopharma, Inc. reported the year ended December 31, 2025 results: revenue $27.5 million.
“The Company reported collaboration revenue of $27.5 million and $9.3 million for the years ended December 31, 2025 and 2024, respectively.”
Earnings Releases
Cue Biopharma, Inc. reported the three months ended December 31, 2025 results: revenue $21.9 million.
“The Company reported collaboration revenue of $21.9 million and $1.6 million for the three months ended December 31, 2025 and 2024, respectively.”
Material Agreements
Cue Biopharma, Inc. entered into Underwriting Agreement with H.C. Wainwright & Co., LLC (effective 2025-12-19).
“On December 19, 2025, Cue Biopharma, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with H.C. Wainwright & Co., LLC, as representative of the several underwriters named therein (collectively, the “Underwriters”), relating to an underwritten public offering”
Governance Changes
Cue Biopharma, Inc.: Increased authorized shares of capital stock from 210,000,000 to 310,000,000 and common stock from 200,000,000 to 300,000,000 (effective 2025-06-05).
“On June 5, 2025, the Company filed a Certificate of Amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware effecting an amendment to increase the number of authorized shares of the Company’s capital stock from 210,000,000 to 310,000,000 and increase the number of authorized shares of the Company’s common stock from 200,000,000 to 300,000,000.”
Daniel R. Passeri changed role as principal financial and accounting officer at Cue Biopharma, Inc..
“Effective June 13, 2025, Daniel R. Passeri, the Company’s Chief Executive Officer, will serve as the Company’s principal financial and accounting officer on an interim basis until a new principal financial and accounting officer is designated.”
Kerri-Ann Millar departed as Chief Financial Officer at Cue Biopharma, Inc..
“On June 4, 2025, Kerri-Ann Millar notified the Company that she is resigning from her position as Chief Financial Officer, effective June 13, 2025.”
Jill Broadfoot was appointed as Director at Cue Biopharma, Inc..
“On June 4, 2025, Jill Broadfoot was appointed to the board of directors (the “Board”) of Cue Biopharma, Inc. (the “Company”), the Audit Committee of the Board, and the Corporate Governance and Nominating Committee of the Board”
Pasha Sarraf was appointed as member of the board of directors at Cue Biopharma, Inc..
“On March 10, 2025, Pasha Sarraf was appointed to the board of directors (the “Board”) of Cue Biopharma, Inc. (the “Company”), following the recommendation of the Corporate Governance and Nominating Committee of the Board.”
Governance Changes
Cue Biopharma, Inc.: Increased authorized shares of capital stock from 110,000,000 to 210,000,000 and authorized shares of common stock from 100,000,000 to 200,000,000 (effective 2024-10-08).
“On October 8, 2024, Cue Biopharma, Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware effecting an amendment to increase the number of authorized shares of the Company’s capital stock from 110,000,000 to 210,000,000 and increase the number of authorized shares of the Company’s common stock from 100,000,000 to 200,000,000.”
Michael J. Fox resigned as Director at Cue Biopharma, Inc..
“On August 28, 2024, Michael J. Fox notified Cue Biopharma, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company (the “Board”) and all committees thereof, effective on August 28, 2024.”
Michael J. Fox was appointed as Director at Cue Biopharma, Inc..
“On June 5, 2024, Michael J. Fox was appointed to the board of directors (the “Board”) and the Compensation Committee of the Board of Cue Biopharma, Inc. (the “Company”), following the recommendation of the Corporate Governance and Nominating Committee of the Board.”
Earnings Releases
Cue Biopharma, Inc. reported first quarter 2024 results: revenue $1.7 million, net income Net loss $(12.3) million, EPS $(0.25) per share.
“disease positions us well to potentially deliver value creation for our shareholders.” First Quarter 2024 Financial Results The Company reported collaboration revenue of $1.7 million and $0.2 million for the three months ended March 31, 2024 and 2023, respectively. The increase was due to revenue earned from our Collaboration and Option Agreement with Ono”
Aaron Fletcher resigned as Member of the Board of Directors at Cue Biopharma, Inc..
“On September 12, 2023, Aaron Fletcher notified Cue Biopharma, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company (the “Board”) and all committees thereof, effective on October 9, 2023.”
Shareholder Votes
Cue Biopharma, Inc. shareholders approved Advisory vote on frequency of future say-on-pay votes at the 2023-06-07 meeting.
“4. The Company’s stockholders recommended, in a non-binding advisory vote, that future advisory votes on the compensation of the Company’s named executive officers be held every one year, with votes cast as follows: One Year Two Years Three Years Abstain Broker Non-Votes 11,090,763 141,546 372,465 2,414,102 17,737,370”
Shareholder Votes
Cue Biopharma, Inc. shareholders approved Non-binding advisory proposal on compensation of named executive officers at the 2023-06-07 meeting.
“3. The Company’s stockholders approved a non-binding advisory proposal on the compensation of the Company’s named executive officers, with votes cast as follows: For Against Abstain Broker Non-Votes 11,079,655 2,042,073 897,148 17,737,370”
Shareholder Votes
Cue Biopharma, Inc. shareholders approved Ratification of appointment of RSM US LLP as independent registered public accounting firm at the 2023-06-07 meeting.
“2. The Company’s stockholders ratified the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, with votes cast as follows: For Against Abstain 30,764,366 105,334 886,546”
Shareholder Votes
Cue Biopharma, Inc. shareholders approved Election of directors at the 2023-06-07 meeting.
“1. The Company’s stockholders elected the following nominees to the Company’s Board of Directors (the “Board”) to serve until the next annual meeting of stockholders and until their resignation or removal or their successors are duly elected and qualified, with votes cast as follows: For Withheld Broker Non-Votes Daniel R. Passeri 11,665,042 2,353,834 17,737,370 Frank Morich 9,236,907 4,781,969 17,737,370 Frederick Driscoll 10,671,595 3,347,281 17,737,370 Aaron Fletcher 11,547,019 2,471,857 17,737,370 Pamela Garzone 11,665,710 2,353,166 17,737,370 Peter A. Kiener 11,650,455 2,368,421 17,737,370 Patrick Verheyen 11,664,063 2,354,813 17,737,370”
Pamela Garzone was appointed as Director at Cue Biopharma, Inc..
“On April 19, 2023, Pamela Garzone was appointed to the board of directors (the “Board”) of Cue Biopharma, Inc.”
Patrick Verheyen was appointed as Director at Cue Biopharma, Inc..
“On April 11, 2023, Patrick Verheyen was appointed to the board of directors (the “Board”) of Cue Biopharma, Inc.”
Ms. Howson departed as Director at Cue Biopharma, Inc..
“On March 7, 2023, Ms. Howson informed the Board of Directors of Cue Biopharma, Inc. (the “Company”) of her intent to retire from the Board of Directors and not stand for re-election at the Company’s 2023 annual meeting of stockholders (the “2023 Annual Meeting”).”
Material Agreements
Cue Biopharma, Inc. entered into Registration Rights Agreement with accredited investors valued at not directly specified (effective 2022-11-14).
“Also on November 14, 2022, the Company entered into a registration rights agreement (the “ Registration Rights Agreement ”) with the Investors, pursuant to which the Company agreed to register for resale the Shares, as well as the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants or the Warrants (the “ Warrant Shares ”).”
Material Agreements
Cue Biopharma, Inc. entered into Securities Purchase Agreement with accredited investors valued at approximately $30.0 million aggregate gross proceeds (effective 2022-11-14).
“On November 14, 2022, Cue Biopharma, Inc., a Delaware corporation (the “ Company ”), entered into securities purchase agreements (together, the “ Securities Purchase Agreement ”) with accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 7,656,966 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), and, in lieu of Shares to certain investors, pre-funded warrants to purchase an aggregate of 1,531,440 shares of Common Stock (the “ Pre-Funded Warrants ”), and, in each case, accompanying warrants (the “ Warrants ”) to purchase an aggregate of up to 9,188,406 additional shares of Common Stock (or Pre-Funded Warrants to purchase Common Stock in lieu thereof) at a price of $3.265 per Share and accompanying Warrant (or $3.2649 per Pre-Funded Warrant and accompanying Warrant) (the “ Offering ”).”
Cameron Gray resigned as Director at Cue Biopharma, Inc..
“On June 16, 2022, Cameron Gray notified Cue Biopharma, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company (the “Board”) and all committees thereof, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.